{"id":50544,"date":"2022-11-07T14:02:44","date_gmt":"2022-11-07T13:02:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"},"modified":"2022-11-07T14:02:44","modified_gmt":"2022-11-07T13:02:44","slug":"affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","title":{"rendered":"Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting"},"content":{"rendered":"<div>\n<p>BOSTON &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.affinittx.com%2F&amp;esheet=52962097&amp;newsitemid=20221107005425&amp;lan=en-US&amp;anchor=Affini-T+Therapeutics%2C+Inc&amp;index=1&amp;md5=4a7808a3bf9e6e59c5b79cc92bd807db\" rel=\"nofollow noopener\" shape=\"rect\">Affini-T Therapeutics, Inc<\/a>., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its oncogenic driver programs targeting KRAS G12V will be presented at the Society for Immunotherapy of Cancer (SITC) 37<sup>th<\/sup> Annual Meeting.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221107005425\/en\/1396868\/5\/Affini-T_Therapeutics_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221107005425\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg\"><\/a><\/p>\n<p>\n\u201c<!-- no quote -->Patients are the central motivation for all of our work at Affini-T, and now is an exciting time to be in the KRAS drug development space \u2013 tackling hard-to-treat solid tumors for patients with high unmet needs,\u201d said Lo\u00efc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. \u201c<!-- no quote -->We have observed encouraging preclinical potency and selectivity data for our KRAS G12V TCR-T cell therapy candidates that support further clinical translation and development. We look forward to presenting our findings at the SITC Conference in Boston.\u201d\n<\/p>\n<p>\n<b>Oral Presentation and Poster details are as follows:<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b><span class=\"bwuline\">Abstract #244 Oral presentation:<\/span><\/b><span class=\"bwuline\"> Clinical Session 206 Nov 11<sup>th<\/sup> 12:10-1:10 pm ET<\/span> (and poster presentation Nov 11<sup>th<\/sup> 11:55 am-1:25 pm and 7:00-8:30 pm ET): AFNT-111, a preclinically safe and effective TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V mutation &#8211; Presenting Author: Hubert Lam, Ph.D., Vice President, Preclinical Development, Affini-T Therapeutics\n<\/li>\n<li>\n<b><span class=\"bwuline\">Abstract #342 Poster presentation<\/span><\/b><span class=\"bwuline\">: Nov 11<sup>th<\/sup> 11:55 am-1:25 pm and 7:00-8:30 pm ET<\/span>: KRAS G12V T cell receptor-engineered T cells expressing the durability FAS-41BB switch receptor exhibit a potent, persistent, coordinated CD4\/CD8 anti-tumor response in vitro and in vivo &#8211; Presenting Author: Gary Shapiro, Ph.D., Vice President, Discovery Biology, Affini-T Therapeutics\n<\/li>\n<\/ul>\n<p>\n<b>About Affini-T Therapeutics<\/b>\n<\/p>\n<p>\nAffini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Faffini-t-therapeutics%2F&amp;esheet=52962097&amp;newsitemid=20221107005425&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=5b27c31cbeac83b04a2ff3c919140862\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Faffinit_tx&amp;esheet=52962097&amp;newsitemid=20221107005425&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=bf1f1c2c02396df96b58890da9c1602a\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Contacts<\/b><br \/>Danielle Cantey<br \/>\n<br \/>Evoke Canale<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#x3a;&#x44;&#97;&#x6e;i&#101;&#x6c;l&#101;&#x2e;&#67;&#x61;n&#116;&#x65;y&#64;&#x65;&#118;&#x6f;&#x6b;&#101;&#x67;r&#111;&#x75;p&#x2e;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">Dani&#101;&#108;&#108;&#101;&#46;&#x43;&#x61;&#x6e;&#x74;&#x65;&#x79;&#x40;evok&#101;&#103;&#114;&#111;&#117;&#x70;&#x2e;&#x63;&#x6f;&#x6d;<\/a><br \/>619-826-4657\n<\/p>\n<p>\nIan Stone<br \/>\n<br \/>Canale Communications<b><br \/><\/b><a target=\"_blank\" href=\"ma&#105;&#108;&#116;&#111;&#x3a;&#x49;&#x61;&#x6e;&#x2e;st&#111;&#110;&#101;&#64;&#x63;&#x61;&#x6e;&#x61;&#x6c;ec&#111;&#109;&#109;&#46;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x49;&#97;n&#x2e;&#x73;&#116;o&#x6e;&#x65;&#64;c&#x61;&#x6e;&#97;l&#x65;&#x63;&#111;m&#x6d;&#46;&#99;o&#x6d;<\/a><br \/>619-849-5388\n<\/p>\n<p>\n<b>Investor Contact<br \/>\n<br \/><\/b>Ailsa Dalgliesh, Ph.D.<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#116;&#111;&#58;ai&#x6c;&#x73;&#x61;&#x40;&#x61;&#102;&#102;&#105;ni&#x74;&#x74;&#x78;&#x2e;&#x63;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">a&#105;&#108;&#x73;&#x61;&#x40;a&#102;&#102;&#x69;&#x6e;&#x69;tt&#120;&#x2e;&#x63;&#x6f;m<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its oncogenic driver programs targeting KRAS G12V will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. \u201cPatients are the central motivation for all of our work &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50544","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its oncogenic driver programs targeting KRAS G12V will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. \u201cPatients are the central motivation for all of our work ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-07T13:02:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221107005425\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting\",\"datePublished\":\"2022-11-07T13:02:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\"},\"wordCount\":406,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107005425\\\/en\\\/1396868\\\/21\\\/Affini-T_Therapeutics_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\",\"name\":\"Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107005425\\\/en\\\/1396868\\\/21\\\/Affini-T_Therapeutics_logo.jpg\",\"datePublished\":\"2022-11-07T13:02:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107005425\\\/en\\\/1396868\\\/21\\\/Affini-T_Therapeutics_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107005425\\\/en\\\/1396868\\\/21\\\/Affini-T_Therapeutics_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Pharma Trend","og_description":"BOSTON &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its oncogenic driver programs targeting KRAS G12V will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. \u201cPatients are the central motivation for all of our work ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-07T13:02:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221107005425\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","datePublished":"2022-11-07T13:02:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"},"wordCount":406,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221107005425\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","name":"Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221107005425\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg","datePublished":"2022-11-07T13:02:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221107005425\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221107005425\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50544"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50544\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}